These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6666861)

  • 1. Distribution of testosterone in plasma proteins during replacement therapy with testosterone enanthate in patients suffering from hypogonadism.
    Demisch K; Nickelsen T
    Andrologia; 1983; 15 Spec No():536-41. PubMed ID: 6666861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.
    Zgliczynski S; Ossowski M; Slowinska-Srzednicka J; Brzezinska A; Zgliczynski W; Soszynski P; Chotkowska E; Srzednicki M; Sadowski Z
    Atherosclerosis; 1996 Mar; 121(1):35-43. PubMed ID: 8678922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone profiles after intramuscular injection of testosterone enanthate in patients with hypogonadism.
    Nakazawa R; Baba K; Nakano M; Katabami T; Saito N; Takahashi T; Iwamoto T
    Endocr J; 2006 Jun; 53(3):305-10. PubMed ID: 16710076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex hormone-binding globulin changes with androgen replacement.
    Plymate SR; Leonard JM; Paulsen CA; Fariss BL; Karpas AE
    J Clin Endocrinol Metab; 1983 Sep; 57(3):645-8. PubMed ID: 6683724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
    Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
    J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low sex hormone-binding globulin and testosterone levels in association with erectile dysfunction among human immunodeficiency virus-infected men receiving testosterone and oxandrolone.
    Wasserman P; Segal-Maurer S; Rubin D
    J Sex Med; 2008 Jan; 5(1):241-7. PubMed ID: 17961146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypogonadal men treated with oral testosterone undecanoate.
    Sarris S; Swyer GI; Lawrence DM
    Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
    Dobs AS; Hoover DR; Chen MC; Allen R
    J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
    Gittelman M; Jaffe JS; Kaminetsky JC
    J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypogonadism and androgen replacement therapy in elderly men.
    Basaria S; Dobs AS
    Am J Med; 2001 May; 110(7):563-72. PubMed ID: 11343670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
    Anderson RA; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone.
    Coviello AD; Lakshman K; Mazer NA; Bhasin S
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4669-75. PubMed ID: 16912120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density.
    Dabaja AA; Bryson CF; Schlegel PN; Paduch DA
    BJU Int; 2015 Mar; 115(3):480-5. PubMed ID: 25046796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.